Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain ...

Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

Annovis Bio Inc. shares saw heightened volatility early Tuesday after the FDA approved the final protocol for its pivotal ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...

Annovis Bio (NYSE:ANVS) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted an updated protocol for a ...

In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -0.59% over the last five trades and -13.2 ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio (ANVS – Research Report), retaining the price target of ...

Annovis Bio (ANVS) announced that the FDA has accepted an updated protocol for the pivotal Phase 3 Alzheimer’s Disease study, which is slated ...

Annovis Bio has a 12-month low of $4.53 and a 12-month high of $22.49. Annovis Bio ( NYSE:ANVS – Get Free Report ) last posted its quarterly earnings data on Friday, November 8th.

Annovis Bio (ANVS) announced that the FDA has accepted an updated protocol for the pivotal Phase 3 Alzheimer’s Disease study, which is slated to begin in January 2025. In October 2024 ...